Personalis (PSNL) Projected to Post Quarterly Earnings on Tuesday

Personalis (NASDAQ:PSNL) will likely be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $13.3070 million for the quarter. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 5:00 PM ET.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Trading Up 1.4%

Shares of Personalis stock opened at $9.64 on Friday. The stock has a fifty day simple moving average of $7.02 and a 200 day simple moving average of $5.91. Personalis has a 12-month low of $2.83 and a 12-month high of $10.95. The company has a market capitalization of $854.88 million, a P/E ratio of -7.53 and a beta of 1.83.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Personalis during the 2nd quarter valued at $30,000. BNP Paribas Financial Markets lifted its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Personalis during the 1st quarter valued at $47,000. New York State Common Retirement Fund purchased a new position in shares of Personalis during the 2nd quarter valued at $104,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Personalis during the 2nd quarter valued at $123,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. HC Wainwright restated a “buy” rating and issued a $8.50 price objective on shares of Personalis in a research note on Monday, September 8th. Finally, BTIG Research upped their price objective on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.